Gene expression of endothelin-1 and endothelin receptor A on monocrotaline-induced pulmonary hypertension in rats after bosentan treatment

Korean Circulation Journal

Volumn 40, Issue 9, 2010, Pages 459-464

  Lim, Kyoung Ah ^a   Kim, Kwan Chang ^b   Cho, Min Sun ^b   Lee, Bo En ^b   Kim, Hae Soon ^b   Hong, Young Mi ^b  

^a CHA University   (South Korea)

^b Ewha Womans University School of Medicine   (South Korea)

Author keywords

Bosentan; Endothelin; Gene expression; Monocrotaline; Pulmonary hypertension

Indexed keywords

BOSENTAN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR A; MONOCROTALINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION REGULATION; MALE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PULMONARY ARTERY; PULMONARY HYPERTENSION; QUANTITATIVE ANALYSIS; RAT;

EID: 78149314671     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2010.40.9.459     Document Type: Article

References (32)

1. Kim HW, Kim, Je HG, et al. Pulmonary arterial hypertension in children: a single center experience. Korean Circ J 2008;38:644-50.
2. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-5.
3. Jung JW. Pulmonary arterial hypertension of congenital heart diseases: from reversible pulmonary hypertension to Eisenmenger syndrome. Korean Circ J 2007;37:287-97.
4. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992;85:504-9.
5. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-9.
6. Teerlink JR, Loffler BM, Hess P, Maire JP, Clozel M, Clozel JP. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure: acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). Circulation 1994;90:2510-8.
7. Tuder RM, Marecki JC, Richter A, Fijalkowska I, Flores S. Pathology of pulmonary hypertension. Clin Chest Med 2007;28:23-42, vii.
8. Sakurai T, Yanagisawa M, Masaki T. Molecular characterization of endothelin receptors. Trends Pharmacol Sci 1992;13:103-8.
9. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348:730-2.
10. Zamora MA, Dempsey EC, Walchak SJ, Stelzner TJ. BQ123, an ETA receptor antagonist, inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 1993;9:429-33.
11. Vane J. Endothelins come home to roost. Nature 1990;348:673.
12. de Nucci G, Thomas R, D'Orleans-Juste P, et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A 1988;85:9797-800.
13. Dupuis J, Goresky CA, Stewart DJ. Pulmonary removal and production of endothelin in the anesthetized dog. J Appl Physiol 1994;76: 694-700.
14. Dupuis J, Goresky CA, Fournier A. Pulmonary clearance of circulating endothelin1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol 1996;81:1510-5.
15. Sumner MJ, Cannon TR, Mundin JW, White DG, Watts IS. Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction. Br J Pharmacol 1992;107:858-60.
16. Todd L, Mullen M, Olley PM, Rabinovitch M. Pulmonary toxicity of monocrotaline differs at critical periods of lung development. Pediatr Res 1985;19:731-7.
17. Sohn DW, Kim HK, Kim MA, et al. Beneficial and adverse effects of bosentan treatment in Korean patients with pulmonary artery hypertension. Korean Circ J 2009;39:105-10.
18. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358:1119-23.
19. Clozel M, Hess P, Rey M, Iglarz M, Binkert C, Qiu C. Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats. Exp Biol Med 2006;231:967-73.
20. Kim H, Yung GL, Marsh JJ, et al. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Eur Respir J 2000;15:640-8.
21. Morice AH, Mulrennan S, Clark A. Combination therapy with bosentan and phosphodiesterases inhibitor in pulmonary arterial hypertension. Eur Respir J 2005;26:180-1.
22. Lim KA, Shin JY, Cho SH, Kim KW, Han JJ, Hong YM. Effect of endothelin receptor blokade on monocrotaline-induced pulmonary hypertension in rats. Korean J Pediatr 2009;52:689-95.
23. Miyauchi T, Yorikane R, Sakai S, et al. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotalin-induced pulmonary hypertension. Circ Res 1993; 73:887-97.
24. Itoh T, Nagaya N, Fujii T, et al. A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;169:34-8.
25. Prie S, Leung TK, Cernacek P, Ryan JW, Dupuis J. The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3- diphenyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats. J Pharmacol Exp Ther 1997;282:1312-8.
26. Schermuly RT, Kreisselmeier KP, Ghofrani HA, et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;169:39-45.
27. Park HK, Park SJ, Kim CS, Paek YW, Lee JU, Lee WJ. Enhanced gene expression of renin-angiotensin system, TGF-beta1, endothelin-1 and nitric oxide synthase in right-ventricular hypertrophy. Pharmacol Res 2001;43:265-73.
28. Shiba R, Yanagisawa M, Miyauchi T, et al. Elimination of intravenously injected endothelin-1 from the circulation of the rat. J Cardiovasc Pharmacol 1989;13(Suppl 5):S98-101, discussion S102.
29. Weber C, Schmitt R, Birnboeck H, et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 1996;60:124-37.
30. Loffler BM, Breu V, Clozel M. Effect of different endothelin receptor antagonists and of the novel non-peptide antagonist Ro 46-2005 on endothelin levels in rat plasma. FEBS Lett 1993;333:108-10.
31. Ichikawa KI, Hidai C, Okuda C, et al. Endogenous endothelin-1 mediates cardiac hypertrophy and switching of myosin heavy chain gene expression in rat ventricular myocardium. J Am Coll Cardiol 1996; 27:1286-91.
32. Dai ZK, Tan MS, Chai CY, et al. Effects of sildenafil on pulmonary hypertension and levels of ET-1, eNOS, and cGMP in aorta-banded rats. Exp Biol Med 2006;231:942-7.